Omalizumab, sold under the trade name Xolair, is a medication originally designed to reduce sensitivity to allergens. It has been used to try to control severe allergic asthma, which does not respond to high doses of corticosteroids and less widely for chronic spontaneous urticaria.

Property Value
dbo:abstract
  • Omalizumab, sold under the trade name Xolair, is a medication originally designed to reduce sensitivity to allergens. It has been used to try to control severe allergic asthma, which does not respond to high doses of corticosteroids and less widely for chronic spontaneous urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells. (en)
  • Omalizumab, sold under the brand name Xolair, is a medication originally designed to reduce sensitivity to allergens. It has been used to try to control severe allergic asthma, which does not respond to high doses of corticosteroids and less widely for chronic spontaneous urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells. (en)
  • Omalizumab, sold under the brand name Xolair, is a medication originally designed to reduce sensitivity to allergens. It is typically prescribed to treat severe allergic asthma, which does not respond to high doses of corticosteroids and less widely for chronic spontaneous urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells. (en)
dbo:wikiPageEditLink
dbo:wikiPageExternalLink
dbo:wikiPageExtracted
  • 2020-04-24 12:18:15Z (xsd:date)
  • 2020-05-08 18:54:28Z (xsd:date)
  • 2020-05-09 11:47:24Z (xsd:date)
  • 2020-05-09 11:48:47Z (xsd:date)
  • 2020-05-09 11:54:10Z (xsd:date)
  • 2020-05-09 11:56:28Z (xsd:date)
  • 2020-05-09 11:57:31Z (xsd:date)
  • 2020-05-09 12:00:28Z (xsd:date)
  • 2020-05-09 12:01:27Z (xsd:date)
  • 2020-05-09 12:01:42Z (xsd:date)
  • 2020-05-09 12:44:23Z (xsd:date)
  • 2020-05-10 07:35:46Z (xsd:date)
  • 2020-05-10 10:57:06Z (xsd:date)
  • 2020-05-30 08:03:49Z (xsd:date)
  • 2020-06-14 06:52:53Z (xsd:date)
  • 2020-06-19 20:30:16Z (xsd:date)
  • 2020-08-27 19:21:49Z (xsd:date)
  • 2020-08-27 20:25:07Z (xsd:date)
  • 2020-09-12 03:35:33Z (xsd:date)
  • 2020-09-18 23:21:45Z (xsd:date)
  • 2020-09-18 23:25:00Z (xsd:date)
  • 2020-09-18 23:26:15Z (xsd:date)
  • 2020-09-24 12:48:03Z (xsd:date)
  • 2020-10-08 22:09:53Z (xsd:date)
  • 2020-11-16 14:07:45Z (xsd:date)
  • 2020-12-01 23:43:04Z (xsd:date)
  • 2020-12-07 06:34:59Z (xsd:date)
  • 2020-12-08 23:30:57Z (xsd:date)
  • 2020-12-26 23:21:45Z (xsd:date)
  • 2020-12-29 19:58:54Z (xsd:date)
  • 2021-01-01 22:45:25Z (xsd:date)
  • 2021-01-10 05:25:44Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 1255131 (xsd:integer)
dbo:wikiPageLength
  • 32950 (xsd:integer)
  • 33015 (xsd:integer)
  • 33367 (xsd:integer)
  • 33371 (xsd:integer)
  • 33669 (xsd:integer)
  • 33702 (xsd:integer)
  • 33710 (xsd:integer)
  • 33721 (xsd:integer)
  • 36159 (xsd:integer)
  • 36180 (xsd:integer)
  • 36195 (xsd:integer)
  • 36231 (xsd:integer)
  • 36254 (xsd:integer)
  • 36337 (xsd:integer)
  • 36343 (xsd:integer)
  • 37593 (xsd:integer)
  • 37594 (xsd:integer)
  • 37628 (xsd:integer)
  • 38544 (xsd:integer)
  • 38555 (xsd:integer)
  • 39033 (xsd:integer)
  • 39044 (xsd:integer)
  • 39212 (xsd:integer)
  • 39214 (xsd:integer)
  • 39233 (xsd:integer)
dbo:wikiPageModified
  • 2020-04-24 12:18:09Z (xsd:date)
  • 2020-05-08 18:54:23Z (xsd:date)
  • 2020-05-09 11:47:20Z (xsd:date)
  • 2020-05-09 11:48:40Z (xsd:date)
  • 2020-05-09 11:54:06Z (xsd:date)
  • 2020-05-09 11:56:24Z (xsd:date)
  • 2020-05-09 11:57:26Z (xsd:date)
  • 2020-05-09 12:00:25Z (xsd:date)
  • 2020-05-09 12:01:21Z (xsd:date)
  • 2020-05-09 12:01:35Z (xsd:date)
  • 2020-05-09 12:44:19Z (xsd:date)
  • 2020-05-10 07:35:43Z (xsd:date)
  • 2020-05-10 10:57:00Z (xsd:date)
  • 2020-05-30 08:03:42Z (xsd:date)
  • 2020-06-14 06:52:47Z (xsd:date)
  • 2020-06-19 20:30:08Z (xsd:date)
  • 2020-08-27 19:21:43Z (xsd:date)
  • 2020-08-27 20:25:03Z (xsd:date)
  • 2020-09-12 03:35:28Z (xsd:date)
  • 2020-09-18 23:21:41Z (xsd:date)
  • 2020-09-18 23:24:58Z (xsd:date)
  • 2020-09-18 23:26:10Z (xsd:date)
  • 2020-09-24 12:47:57Z (xsd:date)
  • 2020-10-08 22:09:49Z (xsd:date)
  • 2020-11-16 14:07:41Z (xsd:date)
  • 2020-12-01 23:43:00Z (xsd:date)
  • 2020-12-07 06:34:53Z (xsd:date)
  • 2020-12-08 23:30:52Z (xsd:date)
  • 2020-12-26 23:21:35Z (xsd:date)
  • 2020-12-29 19:58:49Z (xsd:date)
  • 2021-01-01 22:45:19Z (xsd:date)
  • 2021-01-10 05:25:39Z (xsd:date)
dbo:wikiPageOutDegree
  • 52 (xsd:integer)
  • 54 (xsd:integer)
dbo:wikiPageRevisionID
  • 952857380 (xsd:integer)
  • 955604786 (xsd:integer)
  • 955719658 (xsd:integer)
  • 955719801 (xsd:integer)
  • 955720427 (xsd:integer)
  • 955720693 (xsd:integer)
  • 955720801 (xsd:integer)
  • 955721124 (xsd:integer)
  • 955721261 (xsd:integer)
  • 955721286 (xsd:integer)
  • 955725677 (xsd:integer)
  • 955868207 (xsd:integer)
  • 955892653 (xsd:integer)
  • 959721756 (xsd:integer)
  • 962466181 (xsd:integer)
  • 963440685 (xsd:integer)
  • 975289113 (xsd:integer)
  • 975305651 (xsd:integer)
  • 977976555 (xsd:integer)
  • 979127942 (xsd:integer)
  • 979128264 (xsd:integer)
  • 979128368 (xsd:integer)
  • 980072894 (xsd:integer)
  • 982559226 (xsd:integer)
  • 989001668 (xsd:integer)
  • 991816267 (xsd:integer)
  • 992814082 (xsd:integer)
  • 993130881 (xsd:integer)
  • 996495921 (xsd:integer)
  • 997052298 (xsd:integer)
  • 997722541 (xsd:integer)
  • 999442385 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • Omalizumab, sold under the trade name Xolair, is a medication originally designed to reduce sensitivity to allergens. It has been used to try to control severe allergic asthma, which does not respond to high doses of corticosteroids and less widely for chronic spontaneous urticaria. (en)
  • Omalizumab, sold under the brand name Xolair, is a medication originally designed to reduce sensitivity to allergens. It has been used to try to control severe allergic asthma, which does not respond to high doses of corticosteroids and less widely for chronic spontaneous urticaria. (en)
  • Omalizumab, sold under the brand name Xolair, is a medication originally designed to reduce sensitivity to allergens. It is typically prescribed to treat severe allergic asthma, which does not respond to high doses of corticosteroids and less widely for chronic spontaneous urticaria. (en)
rdfs:label
  • Omalizumab (en)
owl:sameAs
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is foaf:primaryTopic of